Bristol-Myers Squibb reports long-term efficacy data for Nujolix

Bristol-Myers Squibb has announced results from a long-term follow-up to a phase III trial that highlights the safety and efficacy of its product Nujolix.

Seven-year results from the BENEFIT trial have demonstrated that the selective T-cell costimulation blocker can deliver a statistically significant 43 percent risk reduction of death or graft loss following a kidney transplant compared to a cyclosporine regimen.

There was also a statistically significant survival benefit, with a 52 percent relative risk reduction of death or graft loss at five years post-transplant. Safety results were broadly similar between Nujolix and cyclosporine.

The product is the first selective T-cell costimulation blocker approved by the US Food and Drug Administration for the prophylaxis of organ rejection in adult patients receiving a kidney transplant.

Dr Douglas Manion, head of specialty development at Bristol-Myers Squibb, said: "The seven-year BENEFIT results mark a significant research milestone for Nulojix and represent our commitment to this patient population."

During the first quarter of the year, Bristol-Myers Squibb experienced a six percent year-on-year rise in revenues, thanks to strong global sales for key brands.